Q-omics provides the consensus-scored FAM83E profile across patient tissues and cancer cell-line models. FAM83E expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FAM83E is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, FAM83E protein abundance shows 28,066 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight ACC, KIRC, and HNSC as cancer lineages where FAM83E shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM83E — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM83E survival associations across molecular data types. FAM83E RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM83E RNA expression–survival associations across cancer types. High FAM83E expression shows unfavorable associations in ACC, KIRC and KIRP, but favorable associations in HNSC, MESO and SCLC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for FAM83E RNA expression.
This table summarizes FAM83E tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FAM83E. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM83E shows lower tumor expression in KIRC, KICH, COAD and LUSC and higher tumor expression in PAAD and STAD. The KIRC box plot shows higher FAM83E RNA expression in normal versus tumor tissue (log2 FC = −0.912, t-test p < 0.001).
This table shows molecular features associated with FAM83E in patient tissues and cancer cell lines. In patient samples, FAM83E shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM83E RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
